Table IV.

Univariate and multivariate cox proportional-hazard regression analysis of overall survival in patients with hepatocellular carcinoma.

	Univariate analysis			Multivariate analysis
Characteristic	HR	95% CI	P-value	HR	95% CI	P-value
Age, ≥65 vs. <65 years	1.34	0.87–2.06	0.18
Sex, female vs. male	1.01	0.57–1.80	0.96
Virus infection, HCV vs. others	1.32	0.84–2.07	0.23
Albumin, <3.5 vs. ≥3.5 g/dl	1.75	1.05–2.92	0.03	1.34	0.63–2.85	0.45
PT, <70 vs. ≥70%	1.51	0.87–2.61	0.14
ICG-R15, ≥15 vs. <15%	1.69	0.95–2.98	0.07
Liver cirrhosis, (+) vs. (−)	1.38	0.90–2.13	0.14
Child-Pugh classification, B vs. A	1.33	0.58–3.06	0.50
Liver damage, B or C vs. A	2.08	1.24–3.49	0.005	1.73	0.80–3.75	0.16
Tumour number, multiple vs. solitary	1.86	1.16–2.97	0.009	1.63	0.81–3.29	0.17
Tumour size, ≥2 vs. <2 cm	1.78	0.82–3.89	0.14
AFP, ≥20 vs. <20 ng/ml	2.30	1.48–3,58	0.0002	1.79	1.10–2.92	0.02
Differentiation, poor vs. good/moderate	2.02	1.04–3.93	0.04	1.18	0.50–2.76	0.71
Growth form, infiltrative vs. expansive	1.69	0.99–2.90	0.05
Formation of capsule, (−) vs. (+)	1.03	0.64–1.66	0.89
Infiltration to capsule, (−) vs. (+)	1.10	0.71–1.70	0.66
Septal formation, (−) vs. (+)	1.04	0.65–1.65	0.87
Serosal invasion, (+) vs. (−)	1.90	1.17–3.09	0.008	1.99	1.17–3.34	0.01
Portal vein or hepatic vein invasion, (+) vs. (−)	2.55	1.61–4.05	<.0001	3.02	1.38–6.61	0.006
Surgical margin, (+) vs. (−)	1.77	1.04–3.02	0.04	1.68	0.90–3.13	0.10
Stage, III/IV vs. I/II	1.68	1.09–2.59	0.02	2.22	0.91–5.42	0.08
YTHDF1 expression, high vs. low	1.22	0.78–1.90	0.38
YTHDF2 expression, high vs. low	1.48	0.90–2.43	0.12

PT, prothrombin time; ICG-R15, indocyanine green 15-min clearance rate; AFP, α-fetoprotein; HCV, hepatitis C virus; YTHDF1/2, YT521-B homology domain family 1/2; HR, hazard ratio.